BIO International Convention
06 - 09 June 2016

Ten companies and organisations from Northern Ireland exhibited at the BIO International Convention, the largest global event for the biotechnology industry.

Northern Ireland has all the right elements for a successful business location. We’re pioneering research in precision medicine with specialisms in oncology, diagnostics and drug discovery. We also offer access to a talented workforce, EU markets and low operating costs and a results-driven way of thinking. And we have an attractive tax regime that’s getting even better.

Read further information below on the Northern Ireland companies that visited.


Who exhibited

Almac Group is a leading contract development and manufacturing organisation, with over 40 years’ experience, providing an extensive range of integrated services to over 600 biopharma companies globally. Services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IRT technology (IVRS/IWRS) through to commercial-scale manufacture.


BioSpyder has developed and commercialized products and services based on TempO-Seq technology, an NGS-based expression profiling assay for hundreds to thousands of genes at very high throughput using standard lab equipment. By avoiding pre-amplification or cDNA synthesis, it delivers unprecedented accuracy and sensitivity even from limited samples.




The Centre for Cancer Research & Cell Biology (CCRCB) specialises in the integration of clinical and scientific investigation to underpin advances relevant to the promotion of personalised cancer medicine. Core to the research is the accredited Molecular Pathology Unit providing real-time diagnostics for patients and a clinically and genetically – annotated tissue repository for use by the research community.

CV6 Therapeutics is a drug development company focused on the generation and commercialization of novel combinational therapies for the treatment of cancer. They use their expertise in mechanisms of drug resistance to develop novel combination therapies that overcome key resistance pathways associated with the most widely used oncology drugs.

Innovation Ulster Ltd (IUL) is Ulster University’s knowledge venturing company. IUL manages Ulster’s market-leading consultancy business, directs investment in technology and incubates high-growth spin out companies. Today their companies are producing life saving devices and therapeutics, sustainable materials for the aerospace industry and revolutionising search engines.


ProAxsis, is developing a range of products for the capture, detection and measurement of active protease biomarkers for diseases including cystic fibrosis and COPD. Their easy-to-use tests incorporate patented “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.

Queen's University Belfast is a top ten research-intensive university with the No.1 Pharmacy School in the UK. Research in the Faculty of Medicine, Health and Life Sciences is creating investible therapies, diagnostics and medical device technologies in oncology, respiratory disease, ophthalmology, diabetes, chronic wound care, HIV and antimicrobials.

The School of Pharmacy at Queen's is one of the leading centres in the UK and internationally for education and research in pharmacy and the pharmaceutical sciences.Or research programmes span a range of scientific and professional disciplines, ranging from drug design and discovery, to formulation and delivery, and on to action and use.




RE-VANA is a drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms. Their prime focus is developing long-acting drug delivery technologies which they seek to partner to organisations developing therapeutics for chronic eye conditions such as age-related macular degeneration, diabetic retinopathy, and glaucoma.

Ulster University is a university with a national and international reputation for excellence, innovation and regional engagement. They make a major contribution to the economic, social and cultural development of Northern Ireland and play a key role in attracting inward investment. They are a major contributor to the Research and Development capacity within Northern Ireland and support local business and industry. The 2008 Research Assessment Exercise confirmed the strength and quality of their research and the advances that we are continually making.